ATARA BIOTHERAPEUTICS, INC. (ATRA) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-21.89M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.31× | Operating cash flow / net income. Period ending 2026-06-30. $-21.89M ÷ $-16.69M ≈ 1.31× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -21.89M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 6.19M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -16.69M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-21.89M | (m) | (m) | $6.19M | (m) | $-16.69M | (m) | (m) | (m) | 1.31× |
| 2026-03-31 | (m) | (m) | $-25.88M | (m) | (m) | $23.14M | (m) | $-9.47M | (m) | (m) | (m) | 2.73× |
| 2025-12-31 | $-50.94M | (m) | $-50.94M | $0.00 | (m) | $120.77M | (m) | $32.69M | (m) | (m) | -42.18% | -1.56× |
| 2025-09-30 | $-69.80M | (m) | $-69.71M | $90.00K | (m) | $151.93M | (m) | $23.40M | (m) | (m) | -45.94% | -2.98× |
| 2025-06-30 | $-64.01M | (m) | $-63.92M | $90.00K | (m) | $188.67M | (m) | $5.79M | (m) | (m) | -33.93% | -11.03× |
| 2025-03-31 | $-67.36M | (m) | $-67.24M | $119.00K | (m) | $199.73M | (m) | $-15.64M | (m) | (m) | -33.73% | 4.30× |
| 2024-12-31 | $-68.96M | (m) | $-68.72M | $246.00K | (m) | $128.94M | (m) | $-85.40M | (m) | (m) | -53.48% | 0.80× |
| 2024-09-30 | $-94.85M | (m) | $-94.65M | $200.00K | (m) | (m) | (m) | $-133.16M | (m) | (m) | (m) | 0.71× |
| 2024-06-30 | $-142.49M | (m) | $-142.01M | $481.00K | (m) | (m) | (m) | $-181.05M | (m) | (m) | (m) | 0.78× |
| 2024-03-31 | $-185.11M | (m) | $-184.16M | $951.00K | (m) | (m) | (m) | $-233.11M | (m) | (m) | (m) | 0.79× |
| 2023-12-31 | $-194.20M | (m) | $-192.98M | $1.22M | (m) | (m) | (m) | $-276.13M | (m) | (m) | (m) | 0.70× |
| 2023-09-30 | $-200.67M | (m) | $-199.45M | $1.22M | (m) | (m) | (m) | $-290.25M | (m) | (m) | (m) | 0.69× |
| 2023-06-30 | $-214.23M | (m) | $-213.16M | $1.07M | (m) | (m) | (m) | $-304.54M | (m) | (m) | (m) | 0.70× |
| 2023-03-31 | $-226.32M | (m) | $-224.33M | $1.99M | (m) | (m) | (m) | $-214.97M | (m) | (m) | (m) | 1.04× |
| 2022-12-31 | $-274.62M | (m) | $-270.43M | $4.19M | (m) | (m) | (m) | $-228.30M | (m) | (m) | (m) | 1.18× |
| 2022-09-30 | $-254.44M | (m) | $-247.82M | $6.62M | (m) | (m) | (m) | $-247.08M | (m) | (m) | (m) | 1.00× |
| 2022-06-30 | $-252.09M | (m) | $-241.74M | $10.35M | (m) | (m) | (m) | $-247.65M | (m) | (m) | (m) | 0.98× |
| 2022-03-31 | $-250.34M | (m) | $-239.35M | $10.99M | (m) | (m) | (m) | $-349.91M | (m) | (m) | (m) | 0.68× |
| 2021-12-31 | $-231.10M | (m) | $-220.52M | $10.58M | (m) | (m) | (m) | $-340.14M | (m) | (m) | (m) | 0.65× |
| 2021-09-30 | $-199.09M | (m) | $-190.37M | $8.71M | (m) | (m) | (m) | $-328.10M | (m) | (m) | (m) | 0.58× |
| 2021-06-30 | $-189.72M | (m) | $-184.35M | $5.36M | (m) | (m) | (m) | $-317.78M | (m) | (m) | (m) | 0.58× |
| 2021-03-31 | $-184.79M | (m) | $-179.41M | $5.38M | (m) | (m) | (m) | $-311.45M | (m) | (m) | (m) | 0.58× |
| 2020-12-31 | $-185.27M | (m) | $-180.76M | $4.51M | (m) | (m) | (m) | $-306.62M | (m) | (m) | (m) | 0.59× |
| 2020-09-30 | $-241.95M | (m) | $-235.33M | $6.62M | (m) | (m) | (m) | $-303.81M | (m) | (m) | (m) | 0.77× |
| 2020-06-30 | $-242.13M | (m) | $-234.52M | $7.61M | (m) | (m) | (m) | $-301.36M | (m) | (m) | (m) | 0.78× |
| 2020-03-31 | $-238.74M | (m) | $-232.47M | $6.27M | (m) | (m) | (m) | $-298.23M | (m) | (m) | (m) | 0.78× |
| 2019-12-31 | $-241.36M | (m) | $-235.63M | $5.73M | (m) | (m) | (m) | $-290.98M | (m) | (m) | (m) | 0.81× |
| 2019-09-30 | $-241.54M | (m) | $-234.35M | $7.19M | (m) | (m) | (m) | $-292.49M | (m) | (m) | (m) | 0.80× |
| 2019-06-30 | $-240.51M | (m) | $-230.31M | $10.20M | (m) | (m) | (m) | $-278.96M | (m) | (m) | (m) | 0.83× |
| 2019-03-31 | $-232.06M | (m) | $-215.15M | $16.91M | (m) | (m) | (m) | $-255.51M | (m) | (m) | (m) | 0.84× |
| 2018-12-31 | $-215.70M | (m) | $-179.77M | $35.92M | (m) | (m) | (m) | $-230.70M | (m) | (m) | (m) | 0.78× |
| 2018-09-30 | $-188.74M | (m) | $-147.29M | $41.45M | (m) | (m) | (m) | $-186.00M | (m) | (m) | (m) | 0.79× |
| 2018-06-30 | $-162.57M | (m) | $-119.42M | $43.15M | (m) | (m) | (m) | $-158.74M | (m) | (m) | (m) | 0.75× |
| 2018-03-31 | $-139.12M | (m) | $-100.29M | $38.83M | (m) | (m) | (m) | $-135.28M | (m) | (m) | (m) | 0.74× |
| 2017-12-31 | $-107.73M | (m) | $-87.50M | $20.23M | (m) | (m) | (m) | $-119.49M | (m) | (m) | (m) | 0.73× |
| 2017-09-30 | $-95.26M | (m) | $-83.73M | $11.53M | (m) | (m) | (m) | $-102.41M | (m) | (m) | (m) | 0.82× |
| 2017-06-30 | $-84.80M | (m) | $-79.08M | $5.72M | (m) | (m) | (m) | $-96.69M | (m) | (m) | (m) | 0.82× |
| 2017-03-31 | $-72.90M | (m) | $-69.57M | $3.33M | (m) | (m) | (m) | $-88.14M | (m) | (m) | (m) | 0.79× |
| 2016-12-31 | $-63.05M | (m) | $-60.02M | $3.02M | (m) | (m) | (m) | $-79.05M | (m) | (m) | (m) | 0.76× |
| 2016-09-30 | $-52.55M | (m) | $-50.25M | $2.30M | (m) | (m) | (m) | $-82.06M | (m) | (m) | (m) | 0.61× |
| 2016-06-30 | $-49.49M | (m) | $-47.57M | $1.92M | (m) | (m) | (m) | $-68.56M | (m) | (m) | (m) | 0.69× |
| 2016-03-31 | $-44.20M | (m) | $-43.02M | $1.18M | (m) | (m) | (m) | $-64.62M | (m) | (m) | (m) | 0.67× |
| 2015-12-31 | $-37.45M | (m) | $-37.16M | $290.00K | (m) | (m) | (m) | $-57.22M | (m) | (m) | (m) | 0.65× |
| 2015-09-30 | $-30.78M | (m) | $-30.72M | $55.00K | (m) | (m) | (m) | $-46.50M | (m) | (m) | (m) | 0.66× |
| 2015-06-30 | $-21.96M | (m) | $-21.91M | $46.00K | (m) | (m) | (m) | $-40.55M | (m) | (m) | (m) | 0.54× |
| 2015-03-31 | $-20.38M | (m) | $-20.33M | $50.00K | (m) | (m) | (m) | $-30.12M | (m) | (m) | (m) | 0.68× |
| 2014-12-31 | $-16.67M | (m) | $-16.63M | $46.00K | (m) | (m) | (m) | $-28.01M | (m) | (m) | (m) | 0.59× |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-5.97M | (m) | $-5.97M | $3.00K | (m) | (m) | (m) | $-8.77M | (m) | (m) | (m) | 0.68× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |